Answers are grounded in this paper and cite their sources.
There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).
No takes yet. Share an insight, caveat, or question.
Dryden‐Peterson et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: